Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma.
Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma.
复制标题
DOI：
10.3389/fonc.2022.1091088
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
中科院分区：
文献类型：
--
作者：
肝细胞癌（HCC）是世界上最常见的肝癌，也是癌症相关死亡的主要原因之一。免疫检查点抑制剂（ICI）和多靶点酪氨酸激酶抑制剂（TKI）或抗血管内皮生长因子（anti-VEGF）抑制剂的单一免疫治疗和联合治疗已成为晚期HCC（aHCC）的新标准治疗。然而，这些治疗的临床益处仍然有限。因此，迫切需要能够预测对免疫疗法的治疗反应以最大化临床益处同时避免不必要的毒性的适当生物标志物。与其他恶性肿瘤相反，到目前为止，没有公认的生物标志物可用于预测HCC患者对免疫治疗的抵抗或反应。此外，在其他癌症类型中建立的生物标志物，如程序性死亡配体1（PD-L1）表达和肿瘤突变负荷（TMB），在HCC中没有稳定的预测作用。因此，针对HCC生物标志物的大量研究正在探索中。在本文中，我们总结了预测和预后生物标志物以及潜在的预测机制，以指导未来肝癌生物标志物探索和临床治疗选择的研究方向。
Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Mono-immunotherapy and combination therapy with immune checkpoint inhibitors (ICIs) and multitargeted tyrosine kinase inhibitors (TKIs) or anti-vascular endothelial growth factor (anti-VEGF) inhibitors have become new standard therapies in advanced HCC (aHCC). However, the clinical benefit of these treatments is still limited. Thus, proper biomarkers which can predict treatment response to immunotherapy to maximize clinical benefit while sparing unnecessary toxicity are urgently needed. Contrary to other malignancies, up until now, no acknowledged biomarkers are available to predict resistance or response to immunotherapy for HCC patients. Furthermore, biomarkers, which are established in other cancer types, such as programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB), have no stable predictive effect in HCC. Thus, plenty of research focusing on biomarkers for HCC is under exploration. In this review, we summarize the predictive and prognostic biomarkers as well as the potential predictive mechanism in order to guide future research direction for biomarker exploration and clinical treatment options in HCC.
登录
查看更多内容
影响因子：
5.2
作者：
Chakrabarti S;Xie H;Urrutia R;Mahipal A
通讯作者：
Mahipal A
分析肝细胞癌的基因组和转录组鉴定了转化生长因子-β途径中的突变和基因表达变化。
影响因子：
29.4
作者：
Chen J;Zaidi S;Rao S;Chen JS;Phan L;Farci P;Su X;Shetty K;White J;Zamboni F;Wu X;Rashid A;Pattabiraman N;Mazumder R;Horvath A;Wu RC;Li S;Xiao C;Deng CX;Wheeler DA;Mishra B;Akbani R;Mishra L
通讯作者：
Mishra L
影响因子：
64.5
作者：
Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu;Cancer Genome Atlas Research Network
通讯作者：
Cancer Genome Atlas Research Network
影响因子：
6.4
作者：
Cheuk, ATC;Mufti, GJ;Guinn, BA
通讯作者：
Guinn, BA
影响因子：
16.6
作者：
Dubin K;Callahan MK;Ren B;Khanin R;Viale A;Ling L;No D;Gobourne A;Littmann E;Huttenhower C;Pamer EG;Wolchok JD
通讯作者：
Wolchok JD